A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations.
A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations.
复制标题
DOI：
10.3233/jad-179904
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Dobson RJB
中科院分区：
文献类型：
--
作者：
Kiddle SJ;Voyle N;Dobson RJB
自从大约25年前发现apoeε4以来，研究人员一直对阿尔茨海默病(AD)血液测试的潜力感到兴奋。从那时起，研究人员一直在寻找AD和相关表型的遗传、蛋白质、代谢物和/或基因表达标记。然而，阿尔茨海默病的血液检测尚未用于临床。我们首先回顾了AD血液生物标记物研究的趋势和挑战，然后给出了帮助研究人员克服这些挑战的个人建议。虽然在独立研究中已经看到了一定程度的一致性和复制，但几项备受瞩目的研究似乎未能复制。部分由于学术动机，该领域不愿报告预测能力，不愿发表负面研究结果，也不愿独立复制他人的工作。如果这个问题可以解决，那么我们将很快知道是否可以开发出具有临床实用价值的AD或相关表型的血液测试。
Ever since the discovery of APOE ε4 around 25 years ago researchers have been excited about the potential of a blood test for Alzheimer's disease (AD). Since then researchers have looked for genetic, protein, metabolite and/or gene expression markers of AD and related phenotypes. However, no blood test for AD is yet being used in the clinical setting. We first review the trends and challenges in AD blood biomarker research, before giving our personal recommendations to help researchers overcome these challenges. While some degree of consistency and replication has been seen across independent studies, several high-profile studies have seemingly failed to replicate. Partly due to academic incentives there is a reluctance in the field to report predictive ability, to publish negative findings and to independently replicate the work of others. If this can be addressed then we will know sooner whether a blood test for AD or related phenotypes with clinical utility can be developed.